Glonghui September 30th 丨Fosun Pharma (600196.SH)Announcement, holding subsidiary ShanghaiFu Hong Han LinBiotechnology Co., Ltd. (hereinafter referred to as “Fuhong Hanlin”) awarded Accord Healthcare Inc. (“Accord”) Permission to exclusively commercialize HLX02 (i.e., trastuzumab for injection; hereafter, “the product”) (including but not limited to commercialization activities such as export, import, promotion, storage, offer sale and distribution) and related rights within the region (i.e. the United States, Canada, the same below).

On September 29, 2020, Fuhong Hanlin, a holding subsidiary of the company, signed “License Terms” with Accord. Fuhong Hanlin plans to grant Accord a license to carry out exclusive commercialization of this product (including but not limited to commercialization activities such as export, import, promotion, storage, sale and distribution) and related rights within the region. The specific arrangements for this cooperation have yet to be further discussed and determined between the two parties. The cooperation is subject to the signing of a final agreement between the two parties and the matters agreed in such agreements shall prevail.

This cooperation does not constitute a related transaction, nor does it constitute a major asset restructuring as stipulated in the “Administrative Measures on Significant Asset Restructurings of Listed Companies”.

This cooperation does not require approval from the company's board of directors or shareholders' meeting.